The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) is a huge mover today! About 432,346 shares traded hands. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has declined 34.20% since February 29, 2016 and is downtrending. It has underperformed by 46.42% the S&P500.
The move comes after 9 months positive chart setup for the $1.33 billion company. It was reported on Oct, 3 by Barchart.com. We have $44.04 PT which if reached, will make NASDAQ:PCRX worth $319.20 million more.
Analysts await Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to report earnings on October, 25. They expect $0.14 EPS, up 40.00% or $0.04 from last year’s $0.1 per share. PCRX’s profit will be $5.24 million for 63.43 P/E if the $0.14 EPS becomes a reality. After $-0.02 actual EPS reported by Pacira Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -800.00% EPS growth.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Ratings Coverage
Out of 10 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 7 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 70% are positive. Pacira Pharmaceuticals has been the topic of 17 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Bank of America upgraded the shares of PCRX in a report on Friday, January 29 to “Buy” rating. The rating was maintained by Brean Capital with “Buy” on Friday, February 26. The rating was downgraded by Brean Capital on Friday, July 1 to “Hold”. The firm has “Buy” rating by Mizuho given on Tuesday, April 19. Mizuho maintained Pacira Pharmaceuticals Inc (NASDAQ:PCRX) on Tuesday, May 3 with “Buy” rating. As per Monday, August 3, the company rating was upgraded by Bank of America. Nomura initiated Pacira Pharmaceuticals Inc (NASDAQ:PCRX) on Tuesday, September 29 with “Buy” rating. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has “Buy” rating given on Monday, September 26 by Jefferies. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has “Underperform” rating given on Wednesday, June 29 by BMO Capital Markets. The firm has “Mkt Outperform” rating given on Tuesday, January 5 by JMP Securities.
According to Zacks Investment Research, “Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.34 in 2016 Q2. Its up 0.39, from 0.95 in 2016Q1. The ratio increased, as 41 funds sold all Pacira Pharmaceuticals Inc shares owned while 39 reduced positions. 36 funds bought stakes while 71 increased positions. They now own 39.74 million shares or 7.79% less from 43.10 million shares in 2016Q1.
Mcf Advisors Limited Liability Co, a Kentucky-based fund reported 200 shares. State Board Of Administration Of Florida Retirement System has invested 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). The Australia-based Westpac Bk Corp has invested 0% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Blackrock Group Inc accumulated 22,844 shares or 0% of the stock. Hoplite Capital Management L P has 1.01% invested in the company for 605,720 shares. The New York-based Tower Cap Limited Liability Company (Trc) has invested 0.02% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Moreover, Sei Investments has 0% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 2,916 shares. Moreover, Counsel Port has 0.2% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 60,416 shares. Barclays Public Ltd, a United Kingdom-based fund reported 23 shares. Price T Rowe Assoc Md last reported 0.03% of its portfolio in the stock. Renaissance Technology Limited Liability Company accumulated 34,800 shares or 0% of the stock. North Star Asset owns 7,400 shares or 0.05% of their US portfolio. Ubs Asset Americas Inc holds 0.01% or 197,606 shares in its portfolio. Kbc Gp Nv accumulated 0% or 511 shares. Janney Montgomery Scott Ltd Liability Com has 0.01% invested in the company for 5,664 shares.
Insider Transactions: Since April 15, 2016, the stock had 0 insider buys, and 8 sales for $3.63 million net activity. The insider Scibetta James S sold $1.13M. Another trade for 600 shares valued at $28,319 was made by Williams Kristen Marie on Monday, June 6. The insider Kronenfeld Mark A. sold $42,255. Shares for $679,800 were sold by STACK DAVID M on Monday, August 15. Riker Lauren Bullaro had sold 938 shares worth $44,706 on Monday, June 6. HASTINGS PAUL J sold $53,335 worth of stock or 1,136 shares. Shares for $46,950 were sold by Brege Laura.
More important recent Pacira Pharmaceuticals Inc (NASDAQ:PCRX) news were published by: Schaeffersresearch.com which released: “Analyst Update: Himax Technologies, Inc., Pacira Pharmaceuticals Inc, and …” on September 26, 2016, also Fool.com published article titled: “Why Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today”, Fool.com published: “Pacira Pharmaceuticals Inc.’s Double-Digit Drop Explained” on May 02, 2016. More interesting news about Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was released by: Finance.Yahoo.com and their article: “Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global …” with publication date: September 01, 2016.
PCRX Company Profile
Pacira Pharmaceuticals, Inc., incorporated on December 22, 2006, is a specialty pharmaceutical company. The Firm is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. The Company’s primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company makes for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.